Monika Pazgan−Simon

Author

Monika Pazgan−Simon

Also Known As

Alexander Sultanbaev, Krzysztof Simon, M Pazgan-Simon, M. Pazgan-Simon, MONIKA PAZGAN-SIMON, Monika Pazgan-Simon, Monika Pazgan‐Simon, Monika Pazgan−Simon

Publications

Citations

H-Index

Concepts

All Affiliations

Wroclaw Medical University Medical University of Silesia Jagiellonian University Medical University of Białystok Poznan University of Medical Sciences

About

Monika Pazgan−Simon is an author at Wroclaw Medical University specializing in medicine, hepatology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	924
2	Health Sciences	5	5	114
3	Public Health	2	2	63
4	Natural Sciences	1	1	23
5	Biochemistry	1	1	23

Monika Pazgan−Simon

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study Shukui Qin, Stephen L. Chan, Shanzhi Gu, The Lancet First-line TherapyHepatologyInternational Phase 3MedicinePathology	2023	590
Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine Piotr Rzymski, Monika Pazgan−Simon, Krzysztof Simon, Vaccines ImmunodeficienciesCovid-19 EpidemiologyVaccine HesitancyCovid-19Hospital Medicine	2021	41
Advanced oxidation protein products and inflammatory markers in liver cirrhosis: a comparison between alcohol-related and HCV-related cirrhosis. Jolanta Zuwała−Jagiełło, Monika Pazgan−Simon, Krzysztof Simon, Acta Biochimica Polonica Liver FibrosisImmunologyLiver CirrhosisPathologyHcv-related Cirrhosis	2011	38
Hepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrence Monika Pazgan−Simon, Krzysztof Simon, Ewa Jarowicz, Clinical and Experimental Hepatology ImmunologyHepatitis BPathologyHepatitis B VirusCirrhosis	2018	34
Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study. Arndt Vogel, Stephen L. Chan, Zhenggang Ren, Journal of Clinical Oncology ImmunologyPathologyImmunotherapeuticsImmunotherapyMetronomic Therapy	2024	31
Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy Robert Flisiak, Dorota Zarębska‐Michaluk, Ewa Janczewska, Cancers Liver FunctionCured Hcv PatientsLiver StiffnessCirrhosisViral Hepatitis	2021	29
Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study Eleni Gkika, Anca-Ligia Grosu, T. Macarulla Mercadé, Cancers Fields ConcomitantHepatologyGliomaAdvanced Hepatocellular CancerMedicine	2022	28
Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC) Monika Pazgan−Simon, Michał Kukla, Jolanta Zuwała−Jagiełło, PLoS ONE PathologyFatty Liver DiseaseSerum VaspinHcc PatientsMetabolic Syndrome	2020	26
Simple demographic characteristics and laboratory findings on admission may predict in-hospital mortality in patients with SARS-CoV-2 infection: development and validation of the covid-19 score Marta Obremska, Monika Pazgan−Simon, Katarzyna Budrewicz, BMC Infectious Diseases	2021	25
Ischemia-modified albumin (IMA) is increased in patients with chronic hepatitis C infection and related to markers of oxidative stress and inflammation. Jolanta Zuwała−Jagiełło, Maria Warwas, Monika Pazgan−Simon Acta Biochimica Polonica	2012	24

Page 1